Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific enrols first patient enrolled in carotid stent study

Boston Scientific : 01 June, 2007  (New Product)
Boston Scientific has enrolled the first patient in the Sonoma post-market approval study of the company's NexStent Carotid Stent System that is used in conjunction with the FilterWire EZ Embolic Protection System.
NexStent is used in conjunction with the FilterWire EZ Embolic Protection System.

The Sonoma study is a multi-centre, US surveillance registry designed to include a minimum of 1,500 patients at 100 sites.

The objective of the study is to confirm the real-world safety and efficacy of the NexStent Carotid Stent System and FilterWire EZ Embolic Protection System in routine clinical practice.

The first patient was enrolled by Subbarao Myla, MD, medical director of
cardiovascular research and vascular intervention, Hoag Heart and Vascular Institute, Hoag Memorial Hospital Presbyterian Newport Beach, California, and principal investigator of the Sonoma study.

'This study represents one of the few multi-centre studies in which shorter-term and longer-term clinical outcomes of carotid artery stenting placement will be reported', said Dr Myla.

'We are hopeful that the unique design and other features of the NexStent Carotid Stent and FilterWire EZ Embolic Protection System will facilitate a high procedure success rate and relatively low risk of major disabling stroke or death in a cohort of patients with symptomatic and asymptomatic carotid artery stenosis that are at high risk for surgery'.

All patients enrolled in the Sonoma study are scheduled for follow-up at 30 days and 12 months following Stent implantation.

In addition, the study will include a cohort of 500 patients whose routine duplex Ultrasound evaluations will be reviewed and analysed by an independent core lab.

The FDA has approved the NexStent Carotid Stent System and FilterWire EZ Embolic Protection System for use in patients with carotid artery disease who are at high risk for surgical carotid endarterectomy.

Compared to surgical alternatives, the NexStent Carotid Stent System and FilterWire EZ Embolic Protection System provide a less-invasive way to treat patients with carotid artery disease.

The NexStent Carotid Stent System includes a laser-cut, nitinol Stent with a rolled sheet design that enables one Stent size to adapt to multiple diameters in tapered or non-tapered vessel configurations.

Its self-sizing feature is intended to provide customization when treating lesions in the carotid arteries, while its closed-cell configuration is designed to increase lesion coverage and to provide a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices.

The FilterWire EZ Embolic Protection System is designed to efficiently capture plaque and other material that may dislodge during Stent implantation, thereby reducing the risk of procedural-related stroke or heart attack.

The system features simplified filter sizing - one size can be placed in vessel diameters between 3.5 and 5.5mm - and is designed for easy preparation, delivery and retrieval.

The Cabernet Trial demonstrated the safety and efficacy of the NexStent Carotid Stent and FilterWire EZ Embolic Protection System.
The study enrolled a total of 454 patients.

Follow-up assessment of 438 patients at 30 days showed a stroke rate of 1.3 percent, and a combined stroke, death, and MI rate of 3.9 percent. The stroke, death and MI rate at one year was 4.7 percent (n = 404).

'Following the successful results of the Cabernet Trial that led to FDA approval, we are looking forward to the outcome of the Sonoma study in evaluating the real-world safety and performance of the NexStent Carotid Stent in conjunction with the FilterWire EZ System', said John Pedersen, president of Boston Scientific's Peripheral Interventions business.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo